BRPI0514543A - sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila - Google Patents

sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila

Info

Publication number
BRPI0514543A
BRPI0514543A BRPI0514543-0A BRPI0514543A BRPI0514543A BR PI0514543 A BRPI0514543 A BR PI0514543A BR PI0514543 A BRPI0514543 A BR PI0514543A BR PI0514543 A BRPI0514543 A BR PI0514543A
Authority
BR
Brazil
Prior art keywords
abiraterone
salts
ester
butyl ether
recovery
Prior art date
Application number
BRPI0514543-0A
Other languages
English (en)
Inventor
Neil John Hunt
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Publication of BRPI0514543A publication Critical patent/BRPI0514543A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SAIS DE METANOSSULFONATO DE ABIRATERONA-3-éSTERES E RECUPERAçãO DE SAIS DE ABIRATERONA-3-éSTERES DE SOLUçãO EM éTER DE TERC-BUTILA DE METILA Um sal de um composto da fórmula (I) pode ser feito com ácido metanossulfónico. O sal e os sais com outros ácidos podem ser preparados por recuperação de éter de terc-butila de metila (MTBE).
BRPI0514543-0A 2004-08-24 2005-08-23 sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila BRPI0514543A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60355904P 2004-08-24 2004-08-24
GBGB0418900.7A GB0418900D0 (en) 2004-08-24 2004-08-24 Novel salt forms
PCT/GB2005/003282 WO2006021776A1 (en) 2004-08-24 2005-08-23 Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abirater one-3-esters from solution in methyl tert-butyl ether

Publications (1)

Publication Number Publication Date
BRPI0514543A true BRPI0514543A (pt) 2008-06-17

Family

ID=33104570

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514543-0A BRPI0514543A (pt) 2004-08-24 2005-08-23 sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila

Country Status (22)

Country Link
US (5) US7700766B2 (pt)
EP (1) EP1789432B1 (pt)
JP (1) JP5069561B2 (pt)
KR (2) KR101245727B1 (pt)
CN (2) CN101044155B (pt)
AT (1) ATE472553T1 (pt)
AU (1) AU2005276298C1 (pt)
BR (1) BRPI0514543A (pt)
CA (1) CA2576922C (pt)
CY (1) CY1110800T1 (pt)
DE (1) DE602005022083D1 (pt)
DK (1) DK1789432T3 (pt)
ES (1) ES2345345T3 (pt)
GB (1) GB0418900D0 (pt)
HK (2) HK1103091A1 (pt)
MX (1) MX2007002032A (pt)
NZ (1) NZ553085A (pt)
PL (1) PL1789432T3 (pt)
PT (1) PT1789432E (pt)
SI (1) SI1789432T1 (pt)
WO (1) WO2006021776A1 (pt)
ZA (1) ZA200701533B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
DK1781683T3 (da) * 2004-08-24 2012-02-06 Btg Int Ltd Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
HUE054495T2 (hu) * 2006-08-25 2021-09-28 Janssen Oncology Inc Rák kezelésére szolgáló készítmény
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Cyp17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102030798B (zh) * 2010-12-17 2012-10-17 深圳万乐药业有限公司 一种醋酸阿比特龙的纯化方法
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
WO2013053691A1 (en) * 2011-10-10 2013-04-18 Zach System Process for preparing 17-substituted steroids
EP2607371A1 (en) 2011-12-23 2013-06-26 Crystal Pharma, S.A.U. Processes for the preparation of abiraterone and related compouds
CN103172690B (zh) * 2011-12-23 2016-08-24 重庆医药工业研究院有限责任公司 醋酸阿比特龙及其中间体的制备方法
CN105461777B (zh) * 2012-01-04 2017-07-18 连云港润众制药有限公司 一种醋酸阿比特龙的纯化方法
CN103254265B (zh) * 2012-02-21 2016-07-13 上海希迈医药科技有限公司 醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN103360458B (zh) * 2012-03-26 2015-05-20 信泰制药(苏州)有限公司 一种阿比特龙的合成方法
CN102731605B (zh) * 2012-06-19 2016-04-13 鲁南制药集团股份有限公司 一种醋酸阿比特龙的纯化方法
CN103665084A (zh) * 2012-09-04 2014-03-26 重庆安格龙翔医药科技有限公司 一种制备醋酸阿比特龙的方法
CN102816200B (zh) * 2012-09-05 2015-04-15 中山大学 一种醋酸阿比特龙的制备方法
CN102816201A (zh) * 2012-09-25 2012-12-12 成都伊诺达博医药科技有限公司 一种阿比特龙的纯化方法
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
ITMI20121788A1 (it) 2012-10-22 2014-04-23 Olon Spa Procedimento per la purificazione di abiraterone acetato
CA2890589A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making abiraterone-3-acetate
EP2917226A1 (en) 2012-11-09 2015-09-16 Synthon BV Process for making the 17-triflate intermediate of abiraterone-3-acetate
TWI570131B (zh) * 2012-11-13 2017-02-11 賽克系統公司 製備17-經取代類固醇之方法
WO2014075978A1 (en) 2012-11-16 2014-05-22 Synthon B.V. Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) * 2012-11-22 2017-04-19 常州靶点医药科技有限公司 一种避免重金属残留的醋酸阿比特龙的制备方法
US9962452B2 (en) 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
CN103242410B (zh) * 2013-05-09 2015-08-26 苏州明锐医药科技有限公司 醋酸阿比特龙的制备方法
IN2013MU02133A (pt) * 2013-06-24 2015-06-05 Sun Pharmaceutical Ind Ltd
KR20160024930A (ko) * 2013-06-28 2016-03-07 시노팜 타이완 리미티드 아비라테론 및 이의 중간체의 제조를 위한 방법
CZ306623B6 (cs) 2013-07-04 2017-04-05 Zentiva, K.S. Soli abirateronu acetátu
EP3080141A1 (en) 2013-12-12 2016-10-19 Basf Se Solid form of abiraterone acetate
EP3099701B1 (en) 2014-01-28 2019-07-24 OLON S.p.A. Procedure for the preparation of abiraterone acetate and intermediates thereof
CN103965282B (zh) 2014-04-21 2016-01-20 武汉百科药物开发有限公司 一种醋酸阿比特龙的制备方法
US9315541B2 (en) * 2014-05-20 2016-04-19 Olon S.P.A. Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
CN105294806A (zh) * 2014-06-13 2016-02-03 江苏希迪制药有限公司 一种制备醋酸阿比特龙中间体的方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
CN104447934B (zh) * 2014-12-08 2017-03-15 深圳科兴生物工程有限公司 一种醋酸阿比特龙的纯化方法
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
WO2018071544A1 (en) 2016-10-11 2018-04-19 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN108586561B (zh) * 2018-04-03 2020-08-04 科兴生物制药股份有限公司 一种制备醋酸阿比特龙的方法
AU2020232706A1 (en) * 2019-03-06 2021-09-16 Propella Therapeutics, Inc. Abiraterone prodrugs
CN112812147A (zh) * 2019-11-15 2021-05-18 江苏佳尔科药业集团股份有限公司 一种醋酸阿比特龙的合成方法及其中间体
WO2022174134A1 (en) 2021-02-15 2022-08-18 Propella Therapeutics, Inc. Abiraterone prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DE69327096T2 (de) 1992-03-31 2000-06-21 Btg Int Ltd 17-substituierte steroide, verwendbar bei behandlung von krebs
ATE176481T1 (de) 1993-09-30 1999-02-15 Btg Int Ltd Synthese von 17-(3-pyridyl) steroiden
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms

Also Published As

Publication number Publication date
MX2007002032A (es) 2007-10-11
CA2576922C (en) 2013-05-07
US20070249836A1 (en) 2007-10-25
US20100152437A1 (en) 2010-06-17
US7700766B2 (en) 2010-04-20
CN101044155B (zh) 2012-10-10
GB0418900D0 (en) 2004-09-29
CA2576922A1 (en) 2006-03-02
US8076474B2 (en) 2011-12-13
HK1103091A1 (en) 2007-12-14
WO2006021776A1 (en) 2006-03-02
US20150329585A1 (en) 2015-11-19
DK1789432T3 (da) 2010-08-16
PL1789432T3 (pl) 2010-11-30
AU2005276298A1 (en) 2006-03-02
US8338588B2 (en) 2012-12-25
NZ553085A (en) 2010-08-27
CY1110800T1 (el) 2015-06-10
EP1789432B1 (en) 2010-06-30
KR101245727B1 (ko) 2013-03-25
KR20120135931A (ko) 2012-12-17
JP2008510780A (ja) 2008-04-10
JP5069561B2 (ja) 2012-11-07
SI1789432T1 (sl) 2010-10-29
US20130090468A1 (en) 2013-04-11
ZA200701533B (en) 2008-08-27
KR101358661B1 (ko) 2014-02-07
CN102863498A (zh) 2013-01-09
AU2005276298C1 (en) 2012-02-02
EP1789432A1 (en) 2007-05-30
CN102863498B (zh) 2015-04-08
ATE472553T1 (de) 2010-07-15
KR20070049171A (ko) 2007-05-10
US20120053340A1 (en) 2012-03-01
HK1180694A1 (en) 2013-10-25
AU2005276298B2 (en) 2011-06-23
ES2345345T3 (es) 2010-09-21
PT1789432E (pt) 2010-08-09
CN101044155A (zh) 2007-09-26
DE602005022083D1 (de) 2010-08-12

Similar Documents

Publication Publication Date Title
BRPI0514543A (pt) sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila
DK1781683T3 (da) Fremgangsmåde til fremstilling af 17-vinyl-triflater som halvfabrikata
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
CY1111671T1 (el) Ετεροκυκλικη ενωση
DK2057126T3 (da) Fremgangsmåde til fremstilling af 3-dihalomethyl-pyrazol-4-carboxylsyrederivater
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
EA200500239A1 (ru) Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
RS53379B (en) N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND THE PROCEDURE FOR THEIR PREPARATION
ME01992B (me) Jedinjenje diarilhidantoina
CR7691A (es) Nuevo procedimiento de sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
CR9369A (es) Compuestos de peridil acido acetico
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
IS7978A (is) Aðferð til að framleiða súr viðbótarsölt af fjölsýrðum basískum samböndum
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
DK1874762T3 (da) Fremgangsmåde til fremstilling af 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamid
EA201270275A1 (ru) Кристаллическое соединение пиридазина
EA201171329A1 (ru) Твердый препарат
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
DOP2011000154A (es) 3-aminociclopentancarboxamidas
DE602006014001D1 (de) Herstellung von 2-aminothiazol-5-carbonsäurederivaten
ATE526302T1 (de) Verfahren zur aufreinigung von hexafluorpropendimeren
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BTG INTERNATIONAL LIMITED (GB)

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110103158/RJ DE 04/10/2011.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements